I don’t want to get into specifics of any one project because for competitive reasons, quite frankly, but there are early stage and there are mid stage and there’s some late stage projects. The later stage ones are the ones probably we could focus on, and we would expect to be achieving — or basically winning or participating in those programs as early as later this year. So it was important to talk about in the prepared remarks to give people a sense of the — Revio has made it such that we can be a strong competitor, and the projects are — have taken notice of Revio. And so not only are we reaching out, people reaching out to us. And I think it’s that combo that’s really powerful. And if we can win some of these deals, of course that will be great for our growth.
So that’s what I’ll say about that for today.
Operator: Thank you. The next question is from John Sourbeer from UBS. Please go ahead.
John Sourbeer: Hi, thanks for taking the question and congrats on the quarter. Just a couple of quick clarifying ones here. China was pretty strong in the quarter. Just any thoughts on how that ramps throughout the year in reopening? And then just a follow-up to that last question. On the third of new customers to PacBio, are those all new to long-read customers? Do you have a sense on how many of those might be maybe existing Oxford Nanopore customers that are converting over? Thanks.
Christian Henry: Yeah. So first of all, China was a really strong result, 40% growth in the quarter, and really it continues to be strong. China, as always, can — as we’ve learned over the last 24 months, can be variable. But I do think Revio and actually Onso are both helping us allay any headwinds that are — that maybe other companies have with respect to China, so new product portfolio certainly helps there. So we see that business continuing to be strong in the year. With respect to new customers, yeah, most of those — when we talk about new customers, they’re generally new to long-read. They’re certainly — they may have done some long-read program projects with service providers, but they’re generally new to long-read.
And some of them have tried Oxford and some of them haven’t, but I don’t know the exact breakdown. What’s interesting is that although we both have long-read technologies, we both attack different parts of the market. And so we don’t see each other as much as maybe one might think. We still do, but maybe not as much as one might think. But it’s exciting to see the industrialization, the scale, the cost advantages of Revio excite even Oxford Nanopore customers.
Operator: And the next question will be from Ross Osborn from Cantor Fitzgerald. Please go ahead.
Ross Osborn: Hi, congrats on the quarter, and thanks for taking our questions. So I guess, first of all, I’ll re-ask Kyle’s question regarding color on your comment that Revio placements matched HiFi demand in the market, as I do not believe it was addressed, but did think that was an interesting comment. And then for my question, can you just walk us through how you’re balancing meeting stronger than anticipated Revio demand while trying to launch Onso without cannibalizing the strong Revio demand?
Christian Henry: Sure. Those are good questions, Ross. So just a little bit of color. What we were trying to point out with that comment was that with Revio launching, we are now increasing the capability for customers to generate HiFi data. And we think that the more HiFi data that is created, that will drive demand for even more HiFi data. And so Revio really is the beginning of the flywheel that drives a fundamental paradigm shift in our mind of how researchers think about their projects and how long-read technology can really go toe to toe with short-read technology and build up significant market. And I think that was really — the point was really that hey, now we’re starting to get that kind of capacity into the world.
